GlassScriptPhysician profile
Ela Mici
NPI 1316419013
$5,107.92
in general payments reported to CMS, 2019-2025
30 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 90% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $326 · 2023: $1,368 · 2024: $2,123 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,781.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.63 | 2023-2025 | |
| Janssen Biotech, INC. | $329.11 | 2023-2025 | Erleada, Tremfya, Akeega |
| Janssen Pharmaceuticals, INC | $268.61 | 2022-2024 | Xarelto |
| Neurocrine Biosciences, INC. | $265.29 | 2022-2024 | Ingrezza, Ongentys |
| Phathom Pharmaceuticals, INC. | $256.99 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $252.37 | 2023 | Rebyota |
| Argenx US, INC. | $247.87 | 2025 | Vyvgart |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.76 | 2022-2024 | Lifevest |
| Sage Therapeutics, LLC | $219.52 | 2024-2025 | |
| Inspire Medical Systems, INC. | $211.03 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $209.33 | 2024-2025 | |
| Neurelis, INC. | $157.58 | 2024 | Valtoco |
| Edwards Lifesciences Corporation | $149.45 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Madrigal Pharmaceuticals | $137.20 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $133.83 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $124.99 | 2025 | Mild Device Kit |
| Glaxosmithkline, LLC. | $124.77 | 2024 | Shingrix |
| Teva Pharmaceuticals USA, INC. | $124.62 | 2024 | Uzedy |
| Sanofi Pasteur INC. | $124.24 | 2022 | |
| Jazz Pharmaceuticals INC. | $122.76 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $120.99 | 2023 | Rexulti |
| Ipsen Biopharmaceuticals, INC | $120.79 | 2025 | Iqirvo |
| Blue Earth Diagnostics | $118.75 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $114.42 | 2023 | Zeposia |
| Genzyme Corporation | $114.06 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $100.69 | 2023 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $99.63 | 2023 | Dupixent |
| Exact Sciences Corporation | $98.67 | 2025 | Cologuard Collection Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.97 | 2024 | |
| Gilead Sciences, INC. | $83.00 | 2023 | Descovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ela Mici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.